Opinions expressed by Forbes Contributors are their own. Dave Wessner is a virologist who covers infectious diseases. Experts convened by the National Academies of Sciences, Engineering, and ...

Orders for Merck ... suggested the drug was not as effective as previously thought. A 30% reduction in the risk of hospitalisation or death in people with mild or moderate COVID-19 at high ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.